Comparison · NCT01256177-dd2f3545
Quetiapine XR vs Placebo: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Quetiapine XR vs Placebo: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment). Trial comparisons, record NCT01256177-dd2f3545. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01256177-dd2f3545
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.633 | 0.55 | 0.709 | wilson | |
| Risk in group 2 | 0.421 | 0.343 | 0.504 | wilson | |
| Risk difference, group 1 minus group 2 | 0.212 | 0.0946 | 0.321 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 1.19 | 1.89 | log | |
| Odds ratio, group 1 over group 2 | 2.37 | 1.46 | 3.83 | log | |
| Number needed to treat, for one more participant with the outcome on Quetiapine XR than on Placebo | 4.72 | 3.12 | 10.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Quetiapine XR | Quetiapine Fumarate (SEROQUEL) Extended Release Tablet administered orally, once daily in the evening. | 88 | 139 | OG001 |
| Group 2 | Placebo | Placebo matching Quetiapine XR. | 59 | 140 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment)
- Description
- Montgomery-Asberg Depression Rating Scale (MADRS) total score range: 0 to 60, the higher the score, the more severe, Remission was defined as MADRS total score ≤12
- Time frame
- After 8 week of start of treatment
- Population
- Full Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
- NCT number
- NCT01256177
- Phases
- PHASE3
- Conditions
- Bipolar Depression
- Interventions
- Quetiapine Fumarate (SEROQUEL) Extended Release, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2016-02-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01256177?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01256177-dd2f3545